SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic tests, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces that it has been awarded Japanese
Patent No. 6771010 entitled, DEVICES AND METHODS OF CELL CAPTURE
AND ANALYSIS. The issued patent covers devices for the detection of
any target of interest, including circulating tumor cells (CTCs)
that are shed into the blood stream by solid tumors where a binding
entity, including antibodies or mixture of binding entities, or
antibodies and any solid surface are used for target capture,
detection, and analysis. This patent includes any biological
sample type of interest and includes the use of single entities or
cocktails of binding entities.
The claims covered by this patent broadly include the use of
binding entities for the capture and detection of any target of
interest on any solid surface. It also covers combinations of
antibodies for capturing a wide variety of different tumor types.
This includes CTCs, as well as any other targets of
interest. This patent combines well with Biocept's patented
microchannel and cell staining platforms. These technologies
combine to enable the capture of any cell of interest, including
very rare cells, that may be present in blood and any other
biological sample type.
"The granting of this Japanese patent broadly expands Biocept's
intellectual property estate for capturing and detecting cells of
interest," said Michael Nall,
Biocept's President and CEO. "The patent also interfaces very
well with our other patented technologies that include our blood
collection tube as well as our Target Selector™ circulating DNA
(ctDNA) analysis platforms used for guiding patient treatment
decisions. We believe the broad coverage of this patent also
provides Biocept with the opportunity for potentially out-licensing
the technology to other companies with a focus on any target of
interest, including single cell analysis and other
methodologies."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, melanoma, and tumors metastatic to the central
nervous system (brain and spinal cord). The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In addition,
Biocept is conducting COVID-19 testing to support efforts to fight
the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve patient
outcomes, our ability to potentially out-license technology, and
the ability of our tests to provide clinically actionable
information to oncologist and their patients, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-broad-japanese-patent-for-the-use-of-binding-entities-in-combination-with-any-solid-surface-to-capture-and-detect-any-target-of-interest-including-ctcs-from-any-sample-type-301166673.html
SOURCE Biocept, Inc.